Atelerix raises £750k for biotech innovation

Atelerix, a biotech spinout from Newcastle University, has successfully raised £750,000 in its latest funding round with notable contributions from ACF Investors and o2h Ventures. This funding will bolster Atelerix's branding and sales efforts as it seeks to revolutionize the storage and transportation of biosamples crucial for drug discovery and pharmaceutical research. By leveraging its hypothermic preservation technology, Atelerix aims to replace traditional cryogenic shipping with a more cost-effective and sustainable solution, maintaining over 90% cell viability for 14 days at room temperature. This technological advancement significantly reduces shipping costs and establishes a new standard in biological transport logistics. The CEO, Alastair Carrington, emphasized the potential of this funding to accelerate global adoption and expand Atelerix's customer base. Sam Fennell of ACF Investors expressed confidence in Atelerix's disruptive platform and strong intellectual property, excited to support the company in transforming the industry. This latest investment round elevates Atelerix's total funding for the year to £1.25 million, paving the way for full-scale commercialization and the conversion of early adopters into loyal customers.